Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Flavio Mavignier Carcano"'
Autor:
Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios, André Fay
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased car
Externí odkaz:
https://doaj.org/article/cc80e2d601e94b1baf2980625067c4c9
Autor:
Luis Eduardo Rosa Zucca, Ana Carolina Laus, Bruna Pereira Sorroche, Eduarda Paro, Luciane Sussuchi, Rui Ferreira Marques, Gustavo Ramos Teixeira, Gustavo Noriz Berardinelli, Lidia Maria Rebolho Batista Arantes, Rui Manuel Reis, Flavio Mavignier Cárcano
Publikováno v:
Translational Oncology, Vol 46, Iss , Pp 102003- (2024)
Methods: One-hundred-six patients diagnosed with non-muscle invasive bladder cancer and treated with intravesical BCG were included and divided into two groups, BCG-responsive (n = 47) and -unresponsive (n = 59). Immunohistochemistry was used to eval
Externí odkaz:
https://doaj.org/article/ff7d1bcc76b645eab8e0504597806a8f
Autor:
Fernando Cotait Maluf, Andrey Soares, Diogo Assed Bastos, Fabio A. B. Schutz, Eduardo Cronemberger, Murilo Luz, Suelen P. S. Martins, David Queiroz Borges Muniz, Flavio Mavignier Carcano, Oren Smaletz, Fábio A Peixoto, Andrea J Gomes, Felipe Melo Cruz, Fabio Franke, Daniel Herchenhorn, Rosemarie Gidekel, Taiane Francieli Rebelatto, Rafaela Gomes, Vinicius Carrera Souza, Andre P. Fay
Publikováno v:
Journal of Clinical Oncology. 40:5076-5076
5076 Background: LACOG 0415 is a phase II, open-label, clinical trial evaluating ADT-free alternatives for advanced castration sensitive prostate cancer (CSPC). Methods: Patients with locally advanced, high-risk biochemical recurrence or metastatic C
Autor:
Daniel D Almeida Preto, Bruno Lordelo, Rosielly Melo Tavares, Nathália Gimenes Afonso, Hadson Silva Araujo, Joao Neif, Luis Eduardo Rosa Zucca, Flavio Mavignier Carcano
Publikováno v:
Journal of Clinical Oncology. 40:e17017-e17017
e17017 Background: Penile cancer is a rare disease worldwide, but in the developing countries represent 2% of male cancers, and sociocultural issues are closely related to risk. Lymph node status is a key prognostic factor, and almost 60% of patients
Autor:
Gustavo Werutsky, Diogo Assed Bastos, Eduardo Cronemberger, Fabio Franke, Telma Santos, Andrey Soares, Fabio A. Peixoto, Suelen Patrícia dos Santos Martins, Flavio Mavignier Carcano, David Queiroz Borges Muniz, Andrea J. Pereira de Santana Gomes, Andre P. Fay, Vinicius Carrera Souza, Fabio A.B. Schutz, Murilo Luz, Rafaela Gomes de Jesus, Felipe Melo Cruz, Daniel Herchenhorn, Vanessa Carvalho Fabricio, Oren Smaletz, Rosemarie Gidekel, Fernando C. Maluf
Publikováno v:
European journal of cancer (Oxford, England : 1990). 158
Background Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for advanced castration-sensitive prostate cancer (CSPC). We investigated ADT-free al
Autor:
Rosana Antunes da Silveira, Luis Eduardo Zucca, Cristovam Scapulatempo-Neto, Sergio Vicente Serrano, João Neif Antonio Junior, Luciano Neder, Henrique César Santejo Silveira, Flávia Gonçalves Fernandes, Adriane Feijó Evangelista, Rui Manuel Reis, André Octavio Nicolau Sanches, Eric Jonasch, Flavio Mavignier Carcano
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 2265, p 2265 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 5
International Journal of Molecular Sciences
Volume 22
Issue 5
Somatic copy number aberrations (CNAs) have been associated with clear-cell renal carcinoma (ccRCC) pathogenesis and are a potential source of new diagnostic, prognostic and therapeutic biomarkers. Recurrent CNAs include loss of chromosome arms 3p, 1
Autor:
André Lopes Carvalho, Marcos Tadeu dos Santos, Ramon de Oliveira Vidal, Cristiano Ribeiro Viana, Cristovam Scapulatempo-Neto, Flavio Mavignier Carcano, Bruno Feres de Souza
Publikováno v:
Journal of Clinical Pathology
AimsCancers of unknown primary sites account for 3%–5% of all malignant neoplasms. Current diagnostic workflows based on immunohistochemistry and imaging tests have low accuracy and are highly subjective. We aim to develop and validate a gene-expre
Autor:
Ana Glenda Santarosa Vieira, Mariana Tomazini Pinto, Eduardo Ramos Martins Cabral, Flavio Mavignier Carcano, Luiz Fernando Lopes
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2349, p 2349 (2021)
Cancers, Vol 13, Iss 2349, p 2349 (2021)
Simple Summary Although testicular germ cell tumors (TGCTs) are rare pediatric malignancies, they are the most common malignancies in young adult men. The similarities and differences between TGCTs in adults and children, taking into account the clin
Autor:
Facundo Zaffaroni, Telma Santos, Andre P. Fay, Carlos Barrios, Vinicius Carrera Souza, David Queiroz Borges Muniz, Fernando C. Maluf, Eduardo Cronemberger, Fabio Ab Schutz, Paulo Ricardo Santos Nunes Filho, Fabio A. Peixoto, Suelen Patricia dos Santos Martins, Flavio Mavignier Carcano, Gustavo Werutsky, Oren Smaletz, Daniel Herchenhorn
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We
Autor:
G. Kenneth Jansz, Neal D. Shore, Paul Ouellette, Flavio Mavignier Carcano, Matthew R. Smith, Christian Kappeler, Sergio Lago, Manuel Philco Salas, Toni Sarapohja, Teuvo L.J. Tammela, Jose Jaime Correa, Larissa De Arruda, Nicolas Lazaretti, Karim Fizazi, Murilo Luz, Marc Pliskin, Oana Petrenciuc, Diogo Assed Bastos, Livia Andrade
Publikováno v:
Journal of Clinical Oncology. 39:240-240
240 Background: DARO is a structurally distinct androgen receptor inhibitor approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) based on significantly prolonged metastasis-free survival compared with PBO (median